A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Seviteronel (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Innocrin Pharmaceuticals
- 31 Jan 2019 Status changed from not yet recruiting to completed.
- 28 Feb 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 28 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.